文献速递临床微生物分子诊断

BD Phoenix NMIC-500面板对革兰阴性杆菌的性能评估

Performance Evaluation of the Newly Developed BD Phoenix NMIC-500 Panel Using Clinical Isolates of Gram-Negative Bacilli.
PubMed 文献 · Ann Lab Med · 2019-01-01

本研究用韩国六家综合医院的450株非重复革兰阴性杆菌临床分离株(409株肠杆菌科和41株葡萄糖非发酵菌),评估BD Phoenix NMIC-500面板进行抗菌药物敏感性试验(AST)和碳青霉烯酶产生菌(CPO)检测的性能。结果显示肠杆菌科除亚胺培南外CA率均>90%,GNFB的CA率为92.7%~100%,面板识别了97.2%的碳青霉烯酶产生分离株。

要点

  • 肠杆菌科CA率除亚胺培南(87.2%)外均>90%。
  • GNFB的CA率为92.7%~100%。
  • 面板识别97.2%的碳青霉烯酶产生分离株。

核心结论

  • BD Phoenix NMIC-500面板在AST和CPO检测方面显示出应用前景。

研究设计与样本

  • 使用450株非重复临床革兰阴性杆菌分离株(409株肠杆菌科和41株葡萄糖非发酵杆菌),来自韩国六家综合医院。
  • 以肉汤微量稀释法作为AST参考方法,并用PCR和测序评估CPO检测准确性。

主要发现

  • 肠杆菌科CA率除亚胺培南(87.2%)外均>90%。
  • GNFB的CA率为92.7%~100%。
  • ME率肠杆菌科为1.7%,GNFB为0%。
  • 面板识别了97.2%(243/250)的碳青霉烯酶产生分离株。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The emergence of carbapenem resistance among gram-negative bacilli (GNB), mediated by carbapenemase production, has necessitated the development of a simple and accurate device for detecting minimum inhibitory concentrations (MICs) and resistance mechanisms, especially carbapenemase production. We evaluated the performance of the BD Phoenix NMIC-500 panel (BD Diagnostic Systems, Sparks, MD, USA) for antimicrobial susceptibility testing (AST) and carbapenemase-producing organism (CPO) detection. METHODS: We used 450 non-duplicate clinical GNB isolates from six general hospitals in Korea (409 Enterobacteriaceae and 41 glucose non-fermenting bacilli [GNFB] isolates). AST for meropenem, imipenem, ertapenem, ceftazidime, and ceftazidime/avibactam, and CPO detection were performed using the Phoenix NMIC-500 panel. Broth microdilution was used as the reference method for AST. The rates of categorical agreement (CA), essential agreement (EA), minor error (mE), major error (ME), and very major error (VME) were calculated in each antimicrobial. In addition, PCR and sequencing were performed to evaluate the accuracy of CPO detection by the BD Phoenix NMIC-500 panel, and the rate of correct identification was calculated. RESULTS: The CA rates were >90% for all antimicrobials tested with the Enterobacteriaceae isolates, except for imipenem (87.2%). The GNFB CA rates ranged from 92.7% to 100% for all antimicrobials. The ME rates were 1.7% for Enterobacteriaceae and 0% for GNFB. The panel identified 97.2% (243/250) of the carbapenemase-producing isolates. CONCLUSIONS: The BD Phoenix NMIC-500 panel shows promise for AST and CPO detection.

来源:Ann Lab Med,查看原文。版权归原作者所有。

引用

  1. Park BY, Mourad D, Hong JS, et al. Performance Evaluation of the Newly Developed BD Phoenix NMIC-500 Panel Using Clinical Isolates of Gram-Negative Bacilli. Ann Lab Med. 2019. PMID: 31037866. doi:10.3343/alm.2019.39.5.470

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。